Clinical Trials Logo

Clinical Trial Summary

Studies using repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory auditory hallucinations (AH) in schizophrenia have shown promise. The majority of studies have examined the effect of low frequency left-sided stimulation (LFL) (i.e., 1 Hz) to the temporal parietal cortex (TPC). Priming stimulation (6 Hz) prior to LFL stimulation (hereby simply referred to as priming) has been shown to enhance the neurophysiological effects of LFL rTMS alone and, as such, may lead to greater attenuation of AH. Therefore, this study evaluated the efficacy of priming rTMS and LFL rTMS, compared to sham, applied to the TPC in patients with schizophrenia experiencing refractory auditory hallucinations (AH).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01386918
Study type Interventional
Source Centre for Addiction and Mental Health
Contact
Status Completed
Phase N/A
Start date February 2004
Completion date January 2009

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04302636 - The Synergistic Effect of Hypoglycemic Index Diet on Refractory Schizophrenia N/A
Recruiting NCT04352569 - Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia N/A
Recruiting NCT03094429 - An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults Phase 2/Phase 3
Completed NCT02377505 - Deep Brain Stimulation in Treatment Resistant Schizophrenia N/A
Recruiting NCT01879956 - Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia N/A
Recruiting NCT02049021 - Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Phase 4